News | Oncology Information Management Systems (OIMS) | April 25, 2019

Philips Unveils IntelliSpace Radiation Oncology at ESTRO 2019

Intelligent patient management solution on display to complement latest radiotherapy imaging and treatment planning innovations

Philips Unveils IntelliSpace Radiation Oncology at ESTRO 2019

April 25, 2019 – Philips announced IntelliSpace Radiation Oncology, an intelligent patient management solution to manage complexity, improve efficiency and enable operational excellence in radiotherapy departments. IntelliSpace Radiation Oncology, which is considered a work in progress and not available for sale, provides a harmonized way of working, integrating applications and automating workflow to help reduce the amount of time it takes from receiving a patient referral to the start of their treatment. The solution is being unveiled at the European Society for Radiation Oncology’s (ESTRO) 38th Annual Meeting, April 26-30 in Milan, Italy.

Radiotherapy is an important and cost-effective part of cancer treatment and control. More than half of all cancer types can be treated with radiotherapy [1], often in combination with other types of therapy such as surgery and chemotherapy. However, radiotherapy is often perceived as a complex treatment option due to the number of clinical specialists and advanced technologies required to deliver effective care. IntelliSpace Radiation Oncology is designed to manage this complexity by providing an integrated platform that connects all the steps from the patient’s referral to the start of their treatment.

The Philips platform is flexible and can be customized to the specific needs of a department and each clinician. It is an open, vendor-agnostic platform designed to provide comprehensive interoperability across the hospital information technology (IT) environment.

To support healthcare providers in capitalizing on the insights and workflow improvement opportunities presented by the platform, Philips is also launching Radiation Oncology Practice Management (also considered a work in progress and not available for sale). This consultancy service will support radiotherapy departments in identifying and acting on data-driven insights to achieve operational excellence.

IntelliSpace Radiation Oncology is the latest addition to Philips’ renewed suite of radiation oncology systems and software. On show for the first time at ESTRO, the new portfolio includes Pinnacle Evolution treatment planning software, Big Bore RT, a dedicated oncology computed tomography (CT) simulator, and the Ingenia Elition 3.0T MR-RT and Ambition 1.5T MR-RT magnetic resonance (MR) systems.

At the show Philips also announced that it plans to expand its MR-only radiotherapy simulation portfolio with MRCAT brain. Based on a single, fast MR scan and leveraging artificial intelligence (AI), Philips’ MRCAT brain will be designed to automatically generate CT-like density information on the MR console. Philips’ MR-only simulation technology, which also includes MRCAT pelvis and prostate, enables clinicians to rely on a single imaging modality by providing both MR’s superior soft-tissue contrast for delineation and density information for dose calculations. The solution is considered a work in progress, is not CE marked, and is not available for sale or distribution.

Philips is also highlighting its partnerships across imaging, planning and treatment support at ESTRO 38. In January 2019, the company announced a collaboration with imaging solutions provider MIM Software Inc., a company that provides practical imaging, automation and data analysis solutions to radiation therapy clinics worldwide. Philips also has an ongoing collaboration with Sun Nuclear to integrate its suite of PlanIQ software into Pinnacle Evolution.

Philips’ collaboration with Elekta has resulted in the introduction of the Elekta Unity, what it calls the world's first high-field MR-linac (linear accelerator). Philips also has a long-standing partnership with IBA, provider of proton beam therapy systems.

For more information: www.usa.philips.com/healthcare

 

References

[1] https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/radiation/basics.html

Related Content

Stronger Distribution Networks to Bolster Radiotherapy Patient Positioning Accessories
News | Patient Positioning Radiation Therapy | July 19, 2019
A recent study projects global market revenues for radiotherapy patient positioning accessories will exceed revenues of...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
RaySearch Releases Version 3A of RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | July 15, 2019
RaySearch has released RayCare 3A, a new version of the next-generation oncology information system (OIS). RayCare is...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...
IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019
Technology | Quality Assurance (QA) | July 10, 2019
IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual...
Researchers Use Artificial Intelligence to Deliver Personalized Radiation Therapy
News | Radiation Therapy | July 09, 2019
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to...